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Obsessive–compulsive disorder (OCD) is a neuropsychiatric disorder. Non-genetic 
factors and their interaction with genes have attracted increasing attention. Epigenetics 
is regarded an important interface between environmental signals and activation/repres-
sion of genomic responses. Epigenetic mechanisms have not previously been examined 
in OCD in children and adolescents. The aim of the present study was to examine the 
DNA methylation profile of selected genes in blood spots from neonates later diagnosed 
with OCD and in the same children/adolescents at the time of diagnosis compared with 
age- and sex-matched controls. Furthermore, we wanted to characterize the association 
of the differential methylation profiles with the severity of OCD and treatment outcome. 
Dried and new blood spot samples were obtained from 21 female children/adolescents 
with verified OCD and 12 female controls. The differential methylation was analyzed 
using a linear model and the correlation with the severity of OCD and treatment outcome 
was analyzed using the Pearson correlation. We evaluated selected Illumina Infinium 
HumanMethylation450 BeadChip probes within and up to 100,000 bp up- and down-
stream of 14 genes previously associated with OCD (SLC1A1, SLC25A12, GABBR1, 
GAD1, DLGAP1, MOG, BDNF, OLIG2, NTRK2 and 3, ESR1, SL6A4, TPH2, and COMT). 
The study found no significantly differential methylation. However, preliminary support 
for a difference was found for the gamma-aminobutyric acid (GABA) B receptor 1 
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(cg10234998, cg17099072) in blood samples at birth and for the estrogen receptor 1 
(ESR1) (cg10939667), the myelin oligodendrocyte glycoprotein (MOG) (cg16650906), 
and the brain-derived neurotrophic factor (BDNF) (cg14080521) in blood samples at 
the time of diagnosis. Preliminary support for an association was observed between the 
methylation profiles of GABBR1 and MOG and baseline severity, treatment effect, and 
responder status; and between the methylation profile of ESR1 and baseline severity. To 
our knowledge, this is the first study to examine the DNA methylation profiles in OCD. 
The study points towards possible differences in the methylation profiles and suggests 
a correlation with the severity of OCD. However, the results warrant further studies in 
larger sample sets.
Keywords: obsessive–compulsive disorder, children, adolescents, epigenetics, estrogen receptor 1, gamma-
aminobutyric acid B receptor 1, myelin oligodendrocyte glycoprotein, association
inTrODUcTiOn
Obsessive–compulsive disorder (OCD) is a frequently encoun-
tered neuropsychiatric disorder with prevalence rates among 
children and adolescents comparable to those of the adult popu-
lation (1–3%) (1). It is characterized by obsessions, i.e., intrusive 
thoughts that are unpleasant and frightening, and which the 
affected individuals attempt to resist or reject and by compul-
sions, i.e., repetitive, often stereotypic movements or mental ritu-
als, which are semi-voluntary and performed to reduce the fear/
anxiety or bodily reaction. OCD is a heterogeneous disorder in 
regard to its clinical presentation and treatment response (2–4). 
Its complex nature has likely complicated efforts to identify causal 
mechanisms associated with this disorder.
Both genetic and non-shared environmental factors are 
important in the etiology of OCD. Based on separate twin mod-
eling analyses, a recent population-based study suggested that the 
increased familial risk of OCD was attributable to additive genetic 
factors (47%). No significant effect could be shown for shared 
environmental factors, whereas non-shared environmental fac-
tors were estimated to be as important as the genetic factors (5).
According to several review articles, genes affecting different 
neurotransmitter systems, neurotrophic factors, and sex hor-
mones have been implicated in OCD (6, 7). It has been suggested 
that these systems form a delicate network of interacting com-
ponents (8). However, as described in the review articles, results 
have been divergent. In association studies, the most stable 
association has been related to SLC1A1, the neuronal glutamate 
transporter gene, which encodes the glutamate transporter 
EACC1 (9) (Table 1). Other components of the glutamatergic 
system have also been associated with OCD. These components 
include genes encoding for the GABA B receptor (GABBR1) 
(10), glutamate decarboxylase 1 (GAD 1) (11), and Disks large-
associated protein 1 (DAP-1) (DLGAP1) (12) (Table  1). Both 
the GABA B receptor and Gad67 are important in regulating the 
activity of glutamate, and DAP-1 is a member of the neuronal 
postsynaptic density complex known to be important in relation to 
the glutamatergic system. Furthermore, myelin oligodendrocyte 
glycoprotein (MOG) has been associated with OCD and with the 
severity of OCD. Moreover, the MOG G511C (Val142Leu) Val/
Val genotype has been associated with morphological changes 
in the total white matter volume in patients with OCD (13). Zai 
and coauthors (14) showed an  association of genetic variants 
and haplotypes within the MOG gene with a further association 
to the severity of OCD (Table 1). The serotonin transporter is 
a main target for the selective serotonin reuptake inhibitors 
(SSRIs), and several studies have investigated the association 
between variants within the gene encoding the serotonin trans-
porter (SLC6A4) and OCD. Positive associations with especially 
early onset OCD have been identified (6, 15) (Table  1). Also, 
the brain-specific tryptophan hydroxylase-2 (TPH-2) enzyme 
involved in the synthesis of serotonin has been associated with 
OCD (16). On the contrary, studies of variations in the COMT 
gene have shown conflicting results (6). However, a recent study 
by Alonso et  al. showed an association between dysfunctional 
beliefs assessed by the Obsessive Beliefs Questionnaire (OBQ-
44) and an interaction between the Val158Met variant in the 
COMT gene and the Val66Met variant in the BDNF gene rather 
than an effect of either variant (17). Other studies have also sug-
gested an association between neurotrophic factors and OCD. 
Hall et  al. showed a strong association between BDNF gene 
variants and OCD (18) pointing towards possible risk alleles 
(including the Val66Met BDNF polymorphism). These findings 
have later been replicated by Hemmings et al. (19) and Katerberg 
et al. (20). Furthermore, Márquez et al. have shown a significant 
association between the occurrence of OCD and genetic vari-
ation at certain BDNF loci suggesting a role for BDNF in the 
development of OCD (21). Furthermore, the BDNF Val66Met 
polymorphism has been implicated in the increased risk of 
OCD resulting from trauma experienced during childhood (22). 
Additionally, it has been suggested that sex hormones may be 
implicated in the development or the worsening of OCD. Forray 
et al. (23) showed a relation between pregnancy and the onset 
of OCD. Furthermore, compared to other women, women with 
onset or worsening of OCD perinatally experienced a worsen-
ing of their OCD in relation to their menstrual period. Alonso 
et  al. (24) investigated the association between variants in the 
estrogen receptor genes (ESR1 and ESR2) and the occurrence of 
OCD. Although no direct association was observed, they found 
that certain OCD subphenotypes (contamination obsessions 
and cleaning compulsions) were associated with both a SNP in 
the ESR1 gene (rs34535804) and a five-marker haplotype in the 
TaBle 1 | Previously published association studies in OcD.
systems gene association studies study type
Glutamatergic system SLC1A1 Positive Dickel et al. (9) Family based
Arnold et al. (42) Family based
Stewart et al. (43) Family based
GABBR1 A tendency for overtransmission Zai et al. (10) Family based
A tendency for association to YBOCS
DLGAP1 Positive Stewart et al. (12) GWAS
MOG Positive Atmaca et al. (13) Case-control
Zai et al. (14) Family-based
Neurotrophic factors OLIG2 Positive Stewart et al. (43) Family-based
NTRK3 Positive Alonso et al. (44) Case-control
NTRK2
BDNF Positive Hall et al. (18) Family based
No association Mossner et al. (45) Family based
Sex hormone Estrogen receptor alpha 1 (ESR1) Positive Alonso et al. (24)
Serotonergic system SLC6A4, 5HTTLPR, and VNTRSTin2 A tendency for an association 
Positive
Walitza et al. (15) Family based
Serotonin transporter Bloch et al. (46) Meta-analysis
Positive Walitza et al. (47) Meta-analysis
TPH2 Overtransmission Mössner et al. (16) Family based
Dopaminergic system Catecholamine-O-methyltransferase (COMT) 
(COMTval158met)
No association Walitza et al. (48) Family based
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ESR1 (5′ end of intron 1). These findings suggest that the ESR1 
gene could contribute to the genetic vulnerability associated 
with OCD manifestations. Furthermore, a study examining the 
severity of Post Traumatic Stress Disorder (PTSD) (often includ-
ing anxiety and OCD) showed that a low level of estradiol could 
promote stronger PTSD symptoms and could be associated with 
poorer fear extinction (25) (Table 1). Apart from the association 
to Disks large-associated protein 1 (DAP-1) (DLGAP1), two 
recent genome-wide association studies (GWAS) were not able to 
replicate the findings from the candidate gene studies described 
above (12, 26). Since several of the associations were described 
either as a combined effect or as being related to epidemiologi-
cal factors, a possible explanation is that the systems exert their 
effect through a delicate network of mutual influences that also 
involve environmental factors influencing the gene transcription 
and expression. Epigenetics is regarded an important interface 
between environmental signals and activation or repression of 
genomic responses. The mechanisms are dynamic and inter-
changeable over time. Through different mechanisms including 
modifications of DNA molecules, the epigenetic mechanisms 
regulate the accessibility for transcription factors and influence 
gene expression (27). The role of epigenetics in anxiety disorders 
has been underlined in studies examining the mechanisms of 
fear-related learning and memory involving histone acetylation 
[reviewed in Ref. (28), where different anxiety mechanisms 
and stress are discussed]. Furthermore, anxiety also involves 
DNA methylation mechanisms where DNA methyltransferases 
are activated by fear learning and associated with methylation 
within the promoter region of the gene encoding the protein 
phosphatase (28). In a publication from 2013, Domschke et al. 
showed a significantly lower GAD1 methylation in adults with 
panic disorder than in age- and sex-matched healthy controls, 
and the occurrence of negative life events correlated with the 
decreased average methylation in a sex-differentiated manner. 
The authors suggested that the hypomethylation could be a 
compensatory reaction (29). A recent study examined the meth-
ylation of SLC6A4 in children with anxiety disorder (30). The 
children were treated with cognitive behavioral therapy (CBT). 
An evaluation of the total group showed no differences in the 
methylation profiles, but comparison of responders with non-
responders showed an increased methylation in one CpG-site 
of the SLC6A4 promotor region in the responders (29). Even 
though several studies have examined epigenetic mechanisms 
in psychiatric disorders including in anxiety disorders, which 
are closely related to OCD, no study has examined epigenetic 
mechanisms in relation to OCD.
In the present study, we wanted to examine the methylation 
profile in selected genomic regions in children and adolescents 
diagnosed with OCD compared with age- and sex-matched 
controls. Furthermore, we wanted to compare the methylation 
profiles at birth and after OCD onset. Finally, we investigated the 
association of the methylation profiles with the severity of OCD 
and with treatment effect. To the best of our knowledge, this is the 
first study to examine the implication of epigenetics mechanisms 
in OCD in a population of children and adolescents.
MaTerials anD MeThODs
Permission to perform the study was granted by the Scientific 
Ethics Committee (1-10-72-149-12).
Children and adolescents were recruited through referrals 
from general practitioners, child mental health specialists, or 
pediatricians. All the children and adolescents were exam-
ined and diagnosed in the specialized OCD clinic in Aarhus, 
Denmark, by a team consisting of experienced and skilled psy-
chologists and a child and adolescent psychiatrist. For diagnostic 
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assessment, we used questions concerning obsessive–compulsive 
symptoms and comorbidity from The Schedule for Affective 
Disorders and Schizophrenia for School-Age Children Present 
and Lifetime Version (K-SADS-PL) (31). The Children’s Yale–
Brown Obsessive–Compulsive Scale (CY-BOCS) (32) was used 
for assessment of severity scores at baseline and after treatment 
with CBT. The CY-BOCS is a clinician-administered instrument 
that evaluates obsessions and compulsions separately on time 
consumed, distress, interference, resistance, and control. It yields 
separate severity scores for obsessions and compulsions (0–20) 
and a composite severity score (0–40). The CY-BOCS scores 
were obtained at the time of diagnosis (defined as pre-treatment 
CY-BOCS scores) and at 13  weeks or at dismissal (defined as 
post-treatment CY-BOCS scores).
Age- and sex-matched controls were recruited through 
advertising at schools and a subsequent contact to parents 
through email or telephone. If the child or adolescent wanted to 
participate, a short interview was conducted that included ques-
tions on anxiety and OCD (ever experienced symptoms). Only 
information on females is presented, since the total number of 
males was very low.
The neonatal blood spot samples from Guthrie cards (referred 
to as “OLD samples” in the following sections) were obtained 
from the Danish Neonatal Screening Biobank (DNSB) located 
in the Statens Serum Institut (SSI). New blood spots (referred to 
as “NEW samples” in the following sections) were collected from 
a fingertip on S&S903 filter paper (33) (GA Whatman) from the 
same individuals at the time of diagnosis. As such, OLD samples 
(neonatal blood samples) and NEW samples were from the same 
individuals, but the samples were taken at different time points. 
Before collecting the blood from the fingertips, the finger was 
cleaned with a wipe with isopropyl alcohol. Next, the area was 
air-dried, and the insert was carried out with a lancette (Microlet, 
Bayer, Germany). The first drop of blood was dried up. A large 
drop of blood was allowed to form on the finger, and then the 
center of the pre-printed circles on filter paper was gently placed 
on the droplet so that it was absorbed. Blood spots were dried at 
room temperature for about 3 h and then kept frozen (−20°C) 
until analysis.
DNA was extracted from the filter paper as previously 
described (34, 35). The epigenetic analysis was conducted 
using the Illumina Infinium HumanMethylation450 Beadchip 
(Illumina San Diego, CA, USA). The degree of methylation 
was examined by beta-values. This method describes the 
percentage methylation of a CpG probe [beta =  methylated/
(methylated + unmethylated)].
We investigated genes in the glutamatergic (SLC1A1, 
SLC25A12, GABBR1, GAD1, DLGAP1, MOG), the serotonergic 
(SLC6A4, TPH2), and the dopaminergic systems (COMT), as 
well as neurotrophic genes (OLIG2, NTRK3, NTRK2, BDNF), 
and the sex hormone receptor (ESR1) (Table 2). The genes and 
their CpGs tags (all CpGs 100,000 bp up and downstream from 
the open reading frame  –  1,486 CpG probes) were selected 
based on hypotheses about gene location, gene function, and the 
results from association studies in relation to OCD (Table 1). 
The selection of CpG sites was performed due to the small 
sample size.
Dna Methylation Variable Positions
The methylation profiles were examined by comparing methyla-
tion beta-values of OCD patients from blood obtained at the time 
of diagnosis (NEW case) with healthy controls (NEW control) of 
comparable age distribution and birth year. Likewise, methylation 
profiles were compared in neonatal blood from the same patients 
(OLD case) and controls (OLD control) obtained from the DNSB. 
For statistical methylation variable positions (MVP) analysis, we 
used the ChAMP package in R (36). Raw data was filtered to 
remove probes with detection p-value >0.01 and bead count <3. 
Likewise, probes aligning to multiple locations and containing 
SNPs identified by Nordlund et al. (37) were also removed. No 
X and Y chromosome hybridizing probes were included in this 
study. This resulted in a total of 434,493 passed probes of the 
485,512 probes in the Illumina Human Methylation 450k array. 
The data were normalized by the SWAN method and converted 
to beta values hereafter batch corrected for technical variation 
by the combat method build into the ChAMP package pipeline.
After filtering with the list of 1,486 hypothesized OCD probes 
(CpG probes located  ±  100.000  bp from the genetic reading 
frame of the selected genes, SLC1A1, GABBR1, GAD1, DLGAP1, 
MOG, TPH2, OLIG2, NTRK3, NTRK2, ESR1, SLC25A12, 
SLC6A4, COMT, and BDNF), 1,368 probes were included for 
further analysis, and the remaining were not used further in this 
study.
Beta values were chosen due to the small sample size. The 
probes were filtered for Det P <  0.01, and a sample Call Rate 
>99% was used (all samples met these criteria). MVPs between 
the case and control group for either the NEW or OLD samples 
were investigated using a linear model across all selected probes, 
and correction for multiple testing was applied by the false dis-
covery rate method (FDR).
Top ranking genes from the MVP association were associated 
with the severity scores (CY-BOCS). Probes ±  100,000  bp up/
downstream of ESR1, MOG, and BDNF were analyzed for the 
NEW cases only; and probes ±  100,000  bp up/downstream of 
GABBR1 and MOG were analyzed for the OLD cases only.
The association between the methylation status and the 
severity of OCD was examined by correlating the methylation 
status and the baseline CY-BOCS score at the time of diagnosis 
and the CY-BOCS differences (post-treatment CY-BOCS scores 
subtracted from baseline CY-BOCS scores). The analysis was 
performed in R by applying the Pearson correlation test between 
scores and probe methylation status across all evaluated probes. 
We corrected for multiple testing using the FDR method.
Treatment response was assigned to cases having a CY-BOCS 
<16 at the end of treatment (week 13). Responder methylation 
status was compared with non-responder methylation status by 
a double-sided t-test across all probes. We corrected for multiple 
testing using the FDR method.
Differential analysis
The difference between methylation status at birth and at the 
time of diagnosis between cases and controls was assessed by dif-
ferential methylation analysis on delta-beta-values [beta-values 
(OLD) minus beta-values (NEW)] with a linear model analysis 
TaBle 2 | Overview of the genes tested for a hypothesized association with OcD and the number of probes included 100,000 bp up and down stream of 
the genetic region – *413 probes were overlapping between GABBR1 and MOG (GABBR1/MOG).
systems gene Probes (count) Methylated variable positions (limma)
case vs. ctrl
OlD (case: N = 21, control: N = 11) neW (case: N = 21, control: N = 12)
Glutamatergic system SLC1A1 28 NS NS
SLC25A12 47 NS NS
GABBR1 519* NS NS
^cg10234998* (GABBR1, TSS1500),
p-val: 0.00023/FDR p 0.18,
Fold-change (case/ctrl): 1.14
^cg17099072* (GABBR1, TSS1500)
p-val: 0.00026/FDR p 0.18
Fold-change (case/ctrl): 1.12
GAD1 87 NS NS
DLGAP1 103 NS NS
MOG 571* NS NS
^cg10234998* (GABBR1, TSS1500),  
p-val: 0.00023/FDR p 0.18,
^cg16650906 (LOC285830, body)
p-val: 0.00017/FDR p 0.12,
Fold-change (case/ctrl): 0.976Fold-change (case/ctrl): 1.14
^cg17099072* (GABBR1, TSS1500)
p-val: 0.00026/FDR p 0.18
Fold-change (case/ctrl): 1.12
Neurotrophic factors BDNF 86 NS NS
^cg14080521 (BDNF-AS, IGR)
p-val: 0.00031/FDR p 0.14,
Fold-change (case/ctrl): 0.98
OLIG2 82 NS NS
NTRK3 51 NS NS
NTRK2 19 NS NS
Sex hormone ESR1 73 NS NS
^cg10939667 (ESR1, Body)
p-val: 0.00016/FDR p 0.12,
Fold-change (case/ctrl): 0.98
Serotonergic system SLC6A4 
(SERT)
63 NS NS
TPH2 42 NS NS
Dopaminergic system COMT 128 NS NS
NS, not-significant describes that a FDR corrected p-value of <0.05 was not achieved for any genetic region. However, we have mentioned (bold writing) the top three probes that 
had p-values <0.2 for each methylation variable position analysis (OLD and NEW) (see the full list of p-values as in Supplementary Material). ^The top three probes with p-values 
<0.2 are written in bold writing, and location abbreviation of the probe position relative to the gene are: TSS1500, 1500 bp upstream from transcription start site; body, in gene 
body; IGR, intergenic region.
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in the ChAMP pipeline between cases and controls. We corrected 
for multiple testing using the FDR method.
resUlTs
Demographic Description of the cohorts
The clinical population consisted of 21 female children and ado-
lescents (13.29 ± 2.63) with verified OCD according to the ICD-
10. The clinical cohort was age- and sex-matched with controls; 
it included 12 females (13.17 ±  2.48) in the NEW cohort and 
11 females (13.18 ± 2.60) in the OLD cohort. The severity of the 
OCD in cases at baseline/pre-treatment was 25.86 ± 5.00 and at 
post-treatment 14.71 ± 5.66 (Table 3). The occurrence of comorbid 
psychiatric disorders is shown in Table 4. Out of the 21 patients, 
8 patients had one comorbid disorder, and 5 patients had more than 
one comorbid disorder (2 or 3 comorbid disorders). None of the 
matched controls had ever experienced OCD or anxiety symptoms.
MVP analysis
The microarray analyses included 21 OLD and NEW case pairs, 
11 OLD controls, and 12 NEW controls.
Comparison of the methylation profiles of female OCD subjects 
(NEW) with the methylation profiles of control subjects (NEW) 
revealed no significant differences in the methylation of CpG sites 
associated with the selected genes. The top-three most altered 
methylation sites in terms of p-value were seen in the body of 
the LOC285830 gene within the chosen range (100,000 bp) of the 
MOG gene on chromosome 6 (probe cg16650906), in the vicin-
ity of the BDNF gene on chromosome 11 (probe cg14080521), 
and in the gene body of the ESR1 gene on chromosome 6 (probe 
TaBle 4 | The occurrence of comorbid disorders in the case group 
(N = 21) described in accordance with the icD 10 diagnostic 
sub-classification.
comorbidity case female
N = 21 (neW and OlD)
Mood disorders 2
Anxiety disorders 4
Trichotillomania 1
Developmental disorders 3
Hyperkinetic disorder 1
Conduct disorder 1
Emotional disorders 6
Tic disorders 4
TaBle 3 | sample statistics of age and Oc symptom severity.
sample statistics case female N = 21 
(neW and OlD)
control female
N = 12 (neW) N = 11 (OlD)
Age 13.29 ± 2.63 13.17 ± 2.48 13.18 ± 2.60
Birth year 1999 ± 2.5 2000 ± 2.6 2000 ± 2.7
CY-BOCS baseline 25.86 ± 5.00 NA
CY-BOCS at 
13 weeks/dismissal
14.71 ± 5.66 NA
Comorbidity 13/21 (61.9%) NA
In the case group, 21 females with clinically diagnosed OCD have been analyzed for 
their methylation profile at birth (OLD) and at the clinical time of diagnosis (NEW). The 
12 females of comparable age distribution were included as NEW controls, and 11 of 
these were included as neonatal controls (OLD) – of comparable birth year distribution. 
Age, year/months, and OC symptom severity (±SD).
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cg10939667). For all sites, the fold-change (case/control) was 0.98 
showing a 2% difference between the cases and the controls. In 
blood samples at birth (OLD), the most altered methylation sites 
were in the GABBR1 gene overlapping with the MOG gene selected 
probes on chromosome 6 (probes cg10234998 and cg17099072). 
The two probes were located close to each other (only 2 bp apart) 
near the GABBR1 transcription start site (TSS1500 shore – within 
1500 bp of the transcription start site) (Table 2). The fold-change 
(case/control) was 1.14 and 1.12, respectively.
No significant MVPs were found in the longitudinal analysis of 
the delta-beta values (OLD-NEW). Still, like in the OLD sample 
MVP analysis, the two same GABBR1/MOG probes (cg17099072 
and cg10234998), as found in the OLD sample MVP analysis, 
showed a differential methylation (FDR p-value 0.135 for both) 
with a fold change (case/control) in delta-beta values of 1.88 and 
1.45, respectively. This effect appears to be inherent from the 
MVP seen in the OLD cohort MVP analysis, where the more 
methylated OLD cases no longer show support for a differentially 
methylation in the NEW cases compared with their respective 
controls (FDR p-values 0.664 and 0.956, respectively).
severity score (cY-BOcs) and 
Treatment responder status  
associated With Methylation status 
in selected Probes
In relation to the severity scores (CY-BOCS), we analyzed 
the probes associated with the MVP top hits both for NEW 
cases: ESR1, MOG (inherently some GABBR1/MOG overlapping 
probes) and BDNF, and for OLD cases: GABBR1 and MOG. 
Neither significant association was found between the methyla-
tion profiles in the OLD cases and baseline CY-BOCS nor were any 
differences found between baseline and differences in CY-BOCS 
scores (post-treatment compared with baseline CY-BOCS scores). 
However, a MOG-associated probe in a CpG island near the gene 
IFITM4P (cg15395148, r = −0.7) had a lower p-value than the 
remaining samples (association to baseline CY-BOCS score), and 
a probe in a CpG island at the 5′ UTR end of the GABBR1 gene 
showed the same tendency (cg19456996, r = −0.7) (association 
to the differences in CY-BOCS scores).
We investigated the correlation of the baseline CY-BOCS and 
CY-BOCS difference in the NEW cases with the methylation 
status of the selected NEW probes and found none of the probes 
to be significantly associated with the scores. However, one ESR1 
probe in the 5′ UTR end of the gene (cg25565730, r = −0.68) and 
two probes selected for MOG, but located within the GABBR1 
gene (cg08967211 and cg17071948, r = −0.64 and −0.65), showed 
a lower p-value than the remaining probes.
Finally, in NEW samples, there was a preliminary support for 
a positive association between the responders and the methyla-
tion state of probes near the MOG gene, where the top scoring 
probe was located in the GABBR1 gene body [cg16922688, 
fold change (responder/non-responder)  =  1.02], while two 
probes in the TSS1500 of the LOC285830 gene, only 9 bp apart 
(cg09567915 and cg11497864) exhibited the same tendency 
of association with comparable fold changes of 1.26 and 1.27, 
respectively (Table 5).
DiscUssiOn
The present study examines the methylation profiles of genes 
hypothesized to be important in OCD in children and adolescents. 
To the best of our knowledge, no other study has investigated 
the methylation status in OCD in children and adolescents or 
examined the difference between methylation status at birth and 
at the time of the OCD diagnosis.
In the present study, differential methylation analysis between 
case and control was performed based on a hypothesis-driven 
selection of genes. We found no MVPs. However, CpG probes in 
GABBR1 and MOG (OLD samples) and probes in MOG, BDNF 
and ESR1 (NEW samples) had the lowest p-values. In OLD 
samples, the study supported an increased methylation of probes 
associated with GABBR1/MOG, whereas in NEW samples, cases 
showed a slightly lower degree of methylation of a CpG in ESR1. 
The extent of modification required in order to achieve functional 
significance is largely unknown. However, methylation changes 
in blood are influenced by the heterogeneous nature of the tissue, 
and markers associated with diseases in the brain are known to be 
of a smaller effect size when analyzed in blood (38).
Previous studies have shown a reduced expression of BDNF 
in relation to anxiety disorders and OCD (39), which could be 
caused by a possible differential methylation in the BDNF gene. 
BDNF has been implicated in fear extinction where it has been 
suggested that the serotonergic and glutamatergic systems may 
mediate their effects on fear through the BDNF gene expression 
TaBle 5 | Top hit genes from MVP analysis of neW (N = 21) (ESR1, MOG, and BDNF) and OlD (MOG and GABBR1) association with cY-BOcs baseline 
(a), cY-BOcs difference from admission until the end of treatment (B) and patient responsiveness to treatment (c) evaluated as a cY-BOcs <16 at the 
end of treatment.
(a) cY-BOcs Baseline cpg gene refgene/feature corr r-value p-value FDr p-value
NEW case (N = 21) cg25565730 ESR1 ESR1, 5′ UTR −0.68 0.0007 0.39
cg08967211 GABBR1/MOG GABBR1, body −0.64 0.0016 0.39
cg17071948 GABBR1/MOG GABBR1, body −0.64 0.0018 0.39
OLD case (N = 21) cg15395148 MOG IFITM4P, IGR −0.70 0.00043 0.26
cg06613392 GABBR1 UBD, IGR −0.65 0.00157 0.48
cg19348622 GABBR1/MOG HLA-F, body −0.60 0.00438 0.89
(B) cY-BOcs DiFFerence cpg gene refgene/feature corr r-value p-value FDr p-value
NEW case (N = 21) cg06380702 MOG IFITM4P, IGR −0.64 0.0019 0.68
cg24764793 ESR1 ESR1, 5′ UTR −0.59 0.0050 0.68
cg10601943 GABBR1/MOG HLA-F, body −0.59 0.0051 0.68
OLD case (N = 21) cg1945699 GABBR1/MOG GABBR1, 5′ UTR −0.70 0.00039 0.24
cg01306985 MOG IFITM4P, TSS1500 −0.62 0.0027 0.52
cg12296326 MOG LOC285830, TSS1500 −0.60 0.0037 0.52
(c) TreaTMenT resPOnDer cpg gene refgene/feature Fold-change p-value FDr p-value
NEW case (N = 21) cg16922688 GABBR1/MOG GABBR1, body 1.02 0.00042 0.15
cg09567915 MOG LOC285830, TSS1500 1.26 0.00048 0.15
cg11497864 MOG LOC285830, TSS1500 1.27 0.00068 0.15
OLD case (N = 21) cg08541345 MOG LOC285830, body 1.30 0.0014 0,52
cg16118803 GABBR1/MOG MOG, body 1.17 0.0019 0.52
cg12463578 GABBR1/MOG ZFP57, first exon 0.84 0.0028 0.52
A and B reflect the correlation between severity scores and beta-values, while C reflects the most different hits between responders and non-responders tested by a parametric 
t-test, and fold change describing the responder/non-responder ratio in the mean beta-value. All p-values are corrected for multiple testing by the FDR method. RefGENE/Chr 
denotes the exact genetic location of the three top-hit probes in each category. 5′ UTR, 5′ untranslated region; body, gene body; IGR, intergenic region; TSS1500, within 1500 bp 
of transcription start site; first exon, in the first exon. Gene investigated by probes in its genetic region and 100,000 bp up/downstream. Exact RefGene and feature of the probe is 
annotated for all top-hit genes in this table.
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(40, 41). Thus, an altered methylation of BNDF probes could 
reflect an altered risk of expressing OCD.
To our knowledge, no previous study has examined the 
methylation status of ESR1 in relation to OCD or anxiety. It 
has been suggested that estrogen receptor genes play a role in 
relation to OCD (24). Even though Alonso et al. could not show 
any difference between controls and subjects with the categori-
cal OCD phenotype, their study identified genetic variants that 
were associated with the presence of certain OCD symptoms. 
This finding suggests that the ESR1 gene could contribute to 
the genetic vulnerability to OCD manifestations. In the present 
study, we observed a tendency towards a reduced methylation 
in NEW female cases compared with NEW female controls and 
tendency towards an inverse correlation between the methylation 
of ESR1 and the pre-treatment severity of OCD (as evaluated by 
the CY-BOCS score). Interestingly, that the altered methylation of 
the ESR1 gene was observed only in NEW samples from female 
cases; that is in females in their teens where estrogens become 
increasingly important and where the sex ratio observed in 
relation to OCD is altered. We only conducted the analyses for 
females, but other studies have shown a sex difference in rela-
tion to the expression of ESR. For example, Delgrange et al. (49) 
showed that the expression of ESR1 was inversely correlated with 
the size and proliferative activity of a prolactin pituitary tumor. 
This finding could suggest a sex-specific receptor expression. The 
associated probes are located in the gene body and in the 5′ end 
of the gene on chromosome 6, respectively. These locations do 
not rule out a regulatory role, and the results could suggest that 
the percentage methylation of the CpG probe plays an important 
role for OCD in females, and for the severity of the disorder. This 
finding would be in accordance with the association between the 
expression of ESR1 and the prognosis of pituitary tumor (47) and 
with the proposed exacerbating role of a low level of estradiol on 
PTSD and the described poorer fear extinction (25). To explore 
the importance of the expression of ESR1 in relation to OCD 
further, future studies could evaluate the degree of methylation 
correlated with the pubertal development in females.
The MOG gene encodes the MOG which is thought to be 
important in the myelination of nerves potentially providing the 
structure of myelin sheath and also in relation to the immune sys-
tem (13, 14). The GABBR1 gene encodes the gamma- aminobutyric 
acid (GABA) B receptor 1 (GABAB1) (10). Through the GABAB1 
receptor, GABA is thought to fine-tune the inhibitory synaptic 
transmission including the effect of glutamate, which has been 
associated with the occurrence of OCD. In the present study, 
probes for the two genes were overlapping showing a potential 
regulatory role for one or both genes. Both GABBR1 and MOG 
showed altered methylation in the blood samples at birth (OLD). 
This may suggest that they are important to the developing brain 
where we may hypothesize that early alterations alter the risk of later 
developing OCD. Both GABA receptor signaling and glutamate 
have been implicated in proliferation, migration, differentiation, 
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and survival processes with a differential expression over lifetime 
(50). The altered methylation of GABBR1/MOC observed in the 
newborn children, however, seemed to stabilize to control levels 
from OLD to NEW cases, as shown by the differential longitudi-
nal analysis of the most significant changes from OLD to NEW. 
MOG (LOC285830) showed an altered methylation in the NEW 
samples. The MOG gene has been associated with the presence of 
OCD, and it has also been related to the severity of the disorder. 
Furthermore, it has been related to changes in white matter and 
to inflammatory processes (13, 14). It is not known whether the 
observed changes arise before the OCD onset or if they could be 
a consequence of having OCD. However, the observed tendency 
towards altered methylation in cases compared with controls and 
in relation to the severity of the disorder and the responder status 
could suggest a regulatory role.
Since methylation levels are not confined to single probes, but 
are more likely to affect entire regions causing differentially meth-
ylated regions, most of these tendencies may be seen as possible 
candidates for future investigation. However, the closely related 
LOC285830 transcription start site probes placed in the vicinity 
of the MOG gene appeared to exhibit uniformly higher methyla-
tion level in treatment responders compared with non-responder 
in the adolescent OCD patients. Furthermore, the consistent 
tendency of the GABBR1 transcription start site probes to have 
at higher methylation level in newborn cases compared with 
controls reveals that epigenetic regional methylation levels might 
indeed be involved in the pathogenesis of OCD, even if no overall 
differentially methylated regions were identified in this study.
liMiTaTiOns
The present study includes only very few patients and controls. 
Nevertheless, it reached nominally significant results and gave 
preliminary support for an association between the methylation 
of ESR1, GABBR1, and MOG and the severity of the OCD and 
treatment outcome. However, due to the limited number of 
patients and controls, the study did not account for potentially 
confounding factors, including parental smoking or illnesses 
in cases/controls at birth. Furthermore, the investigated genes 
were not selected based on GWAS results, which have shown 
different results than candidate gene studies. However, in view 
of the limited number of patients and controls, we chose to focus 
on hypothesis-driven selected genes in a cohort of females. We 
are collecting additional blood specimen from children and 
adolescents with OCD as to perform a future epigenome-wide 
association study. Specimen from the central nervous system 
would have been optimal for examining the methylation patterns. 
However, by necessity, the DNA was extracted from peripheral 
blood rather than from central nervous tissue. It has been dis-
cussed in previous articles that even though the epigenome does 
show tissue-specific patterns, epigenetic modifications may be 
detectable across tissues (51, 52). The specific positions of the 
probes we have examined in the present study and the indicated 
methylation differences are not assessed for their gene regulatory 
functions. However, a larger study providing significant MVPs 
and especially differentially methylated regions would be able to 
link the methylation changes to the annotated genetic regions and 
to speculate on the biological significance.
The findings do not explain the implicated mechanisms, i.e., 
the nominal differences in methylation may be either the cause or 
the result of OCD. Nevertheless, the study supports the hypoth-
esis that epigenetic factors are of importance in mental disorders.
eThical cOnsiDeraTiOns
The study was approved by the ethics committee and was 
conducted in accordance with the latest version of the ethical 
standards as laid down in the 1964 Declaration of Helsinki and 
its later amendments. Informed consent was obtained from the 
participants after the nature of the procedures had been fully 
explained.
aUThOr cOnTriBUTiOns
All authors listed, have made substantial, direct, and intellec-
tual contribution to the work, and approved it for publication. 
However, MH only approved the first edition of the manuscript, 
since he passed away before the final edition was ready.
acKnOWleDgMenTs
The study was funded by AUFF Ideas, project number 438387/
Ideas, Aarhus University, Denmark.
sUPPleMenTarY MaTerial
The Supplementary Material for this article can be found online 
at http://journal.frontiersin.org/article/10.3389/fpsyt.2016.00035
reFerences
1. Geller DA, Biederman J, Jones J, Shaoiro S, Schwartz S, Park KS. Obsessive-
compulsive disorder in children and adolescents: a review. Harv Rev Psychiatry 
(1998) 5:260–73. doi:10.3109/10673229809000309 
2. Sobin C, Blundell ML, Karayiorgou M. Phenotypic differences in early- and 
late obsessive-compulsive disorder. Compr Psychiatry (2000) 41:373–9. 
doi:10.1053/comp.2000.9009 
3. Nestadt G, Addington A, Samuels J, Liang K-Y, Bienvenu OJ, Riddle M, et al. 
The identification of OCD-related subgroups based on comorbidity. Biol 
Psychiatry (2003) 53:914–20. doi:10.1016/S0006-3223(02)01677-3 
4. Rosario-Campos MC, Leckman JF, Mercadante MT, Shavitt RG, Prado HS, 
Sada P, et  al. Adults with early-onset obsessive-compulsive disorder. Am 
J Psychiatry (2001) 158(11):899–903. 
5. Mataix-Cols D, Boman M, Monzani B, Ruck C, Serlachius E, Langstrom N, 
et  al. Population-based, multigenerational family clustering study of 
 obsessive-compulsive disorder. JAMA Psychiatry (2013) 70:709–17. 
doi:10.1001/jamapsychiatry.2013.3 
6. Walitza S, Wendland JR, Gruenblatt E, Warnke A, Sontag TA, Tucha O, et al. 
Genetics of early-onset obsessive-compulsive disorder. Eur Child Adolescs 
Psychiatry (2010) 19:227–35. doi:10.1007/s00787-010-0087-7 
7. Pauls DL. The genetics of obsessive-compulsive disorder: a review. Dialogues 
Clin Neurosci (2010) 12(2):149–63. 
8. Pauls DL, Abramovitch A, Rauch SL, Geller DA. Obsessive-compulsive disor-
der: an integrative genetic and neurobiological perspective. Nat Rev Neurosci 
(2014) 15:410–24. doi:10.1038/nrn3746 
9. Dickel DE, Veenstra-VanderWeele J, Cox NJ, Wu X, Fischer DJ, Van 
 Etten-Lee  M, et  al. Association testing of the positional and functional 
March 2016 | Volume 7 | Article 359
Nissen et al. DNA Methylation Profiles in OCD
Frontiers in Psychiatry | www.frontiersin.org
candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive  disorder. 
Arch Gen Psychiatry (2006) 63(7):778–85. doi:10.1001/archpsyc.63.7.778 
10. Zai G, Arnold P, Burroughs E, Barr CL, Richter MA, Kennedy JL. Evidence 
for the gamma-amino-butyric acid type B receptor 1 (GABBR1) gene as a 
susceptibility factor in obsessive–compulsive disorder. Am J Med Genet B 
(Neuropsych Genet) (2005) 134B:25–9. doi:10.1002/ajmg.b.30152 
11. Mas S, Pagerois M, Gasso P, Ortiz A, Rodriquez N, Morer A, et al. Role of 
GAD2 and HTR1B genes in early-onset obsessive-compulsive disorder: 
results from transmission disequilibrium study. Genes Brain Behav (2014) 
13(4):409–17. doi:10.1111/gbb.12128 
12. Stewart SE, Yu D, Scharf JM, Neale BM, Fagerness JA, Mathews CA, et  al. 
Genome-wide association study of obsessive-compulsive disorder. Mol 
Psychiatry (2013) 18(7):788–98. Davis LK. Erratum in Mol Psychiatry (2013) 
18(7):843 doi:10.1038/mp.2012.85 
13. Atmaca M, Onalan E, Yildirim H, Yuce H, Koc M, Korkmaz S. The associa-
tion of myelin oligodendrocyte glycoprotein gene and white matter volume 
in obsessive-compulsive disorder. J Affect Disord (2010) 124(3):309–13. 
doi:10.1016/j.jad.2010.03.027 
14. Zai G, Bezchlibnyk YB, Richter MA, Arnold P, Burroughs E, Barr CL, et al. 
Myelin oligodendrocyte glycoprotein (MOG) gene is associated with obses-
sive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet (2004) 
129B(1):64–8. doi:10.1002/ajmg.b.30077 
15. Walitza S, Wewetzer C, Gerlach M, Klampfl K, Geller F, Barth N, et  al. 
Transmission disequilibrium studies in children and adolescents with 
obsessive–compulsive disorders pertaining to polymorphisms of genes of the 
serotonergic pathway. J Neural Transm (2004) 111:817–25. 
16. Mössner R, Walitza S, Geller F, Scherag A, Gutknecht L, Jacob C, et  al. 
Transmission disequilibrium of polymorphic variants in the tryptophan 
hydroxylase-2 gene in children and adolescents with obsessive-compulsive 
disorder. Int J Neuropsychopharmacol (2006) 9:437–42. doi:10.1017/
S1461145705005997 
17. Alonso P, López-Solà C, Gratacós M, Fullana MA, Segalàs C, Real E, et al. 
The interaction between Comt and Bdnf variants influences obsessive- 
compulsive-related dysfunctional beliefs. J Anxiety Disord (2013) 27(3):321–7. 
doi:10.1016/j.janxdis.2013.02.012 
18. Hall D, Dhilla A, Charalambous A, Gogos JA, Karayiorgou M. Sequence 
variants of the brain-derived neurotrophic factor (BDNF) gene are strongly 
associated with obsessive-compulsive disorder. Am J Hum Genet (2003) 
73:370–6. doi:10.1086/377003 
19. Hemmings SM, Kinnear CJ, Van der Merwe L, Lochner C, Corfield VA, 
Moolman-Smook JC, et  al. Investigating the role of the brain-derived 
neurotrophic factor (BDNF) val66met variant in obsessive-compulsive 
disorder (OCD). World J Biol Psychiatry (2008) 9:126–34. doi:10.1080/ 
1522970701245003 
20. Katerberg H, Lochner C, Cath DC, de Jonge P, Bochdanovits Z, Moolman-
Smook JC, et  al. The role of brain-derived neurotrophic factor (BDNF) 
val66met variant in the phenotypic expression of obsessive-compulsive dis-
order (OCD). Am J Med Genet B Neuropsychiatr Genet (2009) 150B:1050–62. 
doi:10.1002/ajmg.b.30930 
21. Márquez L, Camarena B, Hernández S, Lóyzaga C, Vargas L, Nicolini H. 
Association study between BDNF gene variants and Mexican patients 
with obsessive-compulsive disorder. Eur Neuropsychopharmacol (2013) 
23(11):1600–5. doi:10.1016/j.euroneuro.2013.08.001 
22. Hemmings SM, Lochner C, Van der Merwe L, Cath DC, Seedat S, 
Stein DJ. BDNF Val66Met modifies the risk of childhood trauma on obsessive- 
compulsive disorder. J Psychiatr Res (2013) 47(12):1857–63. doi:10.1016/j.
jpsychires.2013.08.012 
23. Forray A, Focseneanu M, Pittman B, McDougle CJ, Epperson CN. Onset 
and exacerbation of obsessive-compulsive disorder in pregnancy and the 
postpartum period. J Clin Psychiatry (2010) 71(8):1061–8. doi:10.4088/
JCP.09m05381blu 
24. Alonso P, Gratacòs M, Segalàs C, Escaramís G, Real E, Bayés M, et al. Variants 
in estrogen receptor alpha gene are associated with phenotypical expres-
sion of obsessive-compulsive disorder. Psychoneuroendocrinology (2011) 
36(4):473–83. doi:10.1016/j.psyneuen.2010.07.022 
25. Wegerer M, Kerschbaum H, Blechert J, Wilhelm FH. Low levels of estradiol 
are associated with elevated conditioned responding during fear extinction 
and with intrusive memories in daily life. Neurobiol Learn Mem (2014) 
116:145–54. doi:10.1016/j.nlm.2014.10.001 
26. Mattheisen M, Samuels JF, Wang Y, Greenberg BD, Fyer AJ, McCracken JT, 
et al. Genome-wide association study in obsessive-compulsive disorder: results 
from the OCGAS. Mol Psychiatry (2015) 20:337–44. doi:10.1038/mp.2014.43 
27. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the 
genome integrates intrinsic and environmental signals. Nature Genet (2003) 
33:245–54. doi:10.1038/ng1089 
28. Miller CA, Sweatt JD. Covalent modification of DNA regulates memory for-
mation. Neuron (2007) 53(6):857–69. Erratum in: Neuron (2008) 59(6):1051. 
doi:10.1016/j.neuron.2007.02.022
29. Domschke K, Tidow N, Schrempf M, Schwarte K, Klauke B, Reif A, et  al. 
Epigenetic signature of panic disorder: a role of glutamate decarboxylase 1 
(GAD1) DNA hypomethylation? Prog Neuropsychopharm Biol Psychiatry 
(2013) 46:189–96. doi:10.1016/j.pnpbp.2013.07.014 
30. Roberts S, Lester KJ, Hudson JL, Rapee RM, Creswell C, Cooper PJ, et  al. 
Serotonin transporter methylation and response to cognitive behaviour 
therapy in children with anxiety disorders. Transl Psychiatry (2014) 4(9):e444. 
doi:10.1038/tp.2014.83 
31. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, et  al. 
Schedule for affective disorders and schizophrenia for school-age 
 children-present and lifetime version (K-SADS-PL): initial reliability and 
validity data. J Am Acad Child Adolesc Psychiatry (1997) 36(7):980–8. 
doi:10.1097/00004583-199707000-00021 
32. Scahill L, Riddle MA, McSwiggin-Hardin M, Ort SI, King RA, Goodman WK, 
et  al. Children’s Yale-Brown Obsessive Compulsive Scale: reliability 
and validity. J Am Acad Child Adolesc Psychiatry (1997) 36(6):844–52. 
doi:10.1097/00004583-199706000-00023 
33. Hollegaard MV, Grauholm J, Børglum A, Nyegaard M, Nørgaard-Pedersen B, 
Ørntoft T, et al. Genome-wide scans using archived neonatal dried blood spot 
samples. BMC Genomics (2009) 10:297. doi:10.1186/1471-2164-10-297 
34. Winkel BG, Hollegaard MV, Olesen MS, Svendsen JH, Haunsø S, 
Hougaard DM, et al. Whole-genome amplified DNA from stored dried blood 
spots is reliable in high resolution melting curve and sequencing analysis. 
BMC Med Genet (2011) 12:22. doi:10.1186/1471-2350-12-22 
35. Hollegaard MV, Grove J, Grauholm J, Kreiner-Møller E, Bønnelykke K, 
Nørgaard M, et  al. Robustness of genome-wide scanning using archived 
dried blood spot samples as a DNA source. BMC Genet (2011) 12:58. 
doi:10.1186/1471-2156-12-58 
36. Morris TJ, Butcher LM, Feber A, Teschendorff AE, Chakravarthy AR, 
Wojdacz  TK, et  al. ChAMP: 450k chip analysis methylation pipeline. 
Bioinformatics (2014) 30(3):428–30. doi:10.1093/bioinformatics/btt684 
37. Nordlund J, Bäcklin CL, Wahlberg P, Busche S, Berglund EC, Eloranta ML, 
et al. Genome-wide signatures of differential DNA methylation in pediatric 
acute lymphoblastic leukemia. Genome Biol (2013) 14(9):r105. doi:10.1186/
gb-2013-14-9-r105 
38. Walton E, Hass J, Liu J, Roffman JL, Bernardoni F, Roessner V, et  al. 
Correspondence of DNA methylation between blood and brain tissue and 
its application to schizophrenia research. Schizophr Bull (2015) 42(2):406–14. 
doi:10.1093/schbul/sbv074 
39. Suliman S, Hemmings SM, Seedat S. Brain-derived neurotrophic factor 
(BDNF) protein levels in anxiety disorders: systematic review and meta-
regression analysis. Front Integr Neurosci (2013) 7:55. doi:10.3389/fnint.2013. 
00055 
40. Andero R, Ressler KJ. Fear extinction and BDNF: translating animal 
models of PTSD to the clinic. Genes Brain Behav (2012) 11(5):503–12. 
doi:10.1111/j.1601-183X.2012.00801.x 
41. Andreska T, Aufmkolk S, Sauer M, Blum R. High abundance of BDNF within 
glutamatergic presynapses of cultured hippocampal neurons. Front Cell 
Neurosci (2014) 8:107. doi:10.3389/fncel.2014.00107 
42. Arnold PD, Sicard T, Burroughs E, Richter MA, Kennedy JL. Glutamate trans-
porter gene SLC1A1 associated with obsessive–compulsive disorder. Arch Gen 
Psychiatry (2006) 63:769–76. doi:10.1001/archpsyc.63.7.769 
43. Stewart SE, Fagerness JA, Platko J, Smoller JW, Scharf JM, Illmann C, et al. 
Association of the SLC1A1 glutamate transporter gene and obsessive– 
compulsive disorder. Am J Med Genet B Neuropsychiatr Genet (2007) 
144B:1027–33. doi:10.1002/ajmg.b.30533 
44. Alonso P, Gratacos M, Menchon JM, Saiz-Ruiz J, Segalàs C, Baca-García E, 
et al. Extensive genotyping of the BDNF and NTRK2 genes define protective 
haplotypes against obsessive–compulsive disorder. Biol Psychiatry (2008) 
63:619–28. doi:10.1016/j.biopsych.2007.06.020 
March 2016 | Volume 7 | Article 3510
Nissen et al. DNA Methylation Profiles in OCD
Frontiers in Psychiatry | www.frontiersin.org
45. Mossner R, Walitza S, Lesch KP, Geller F, Barth N, Remschmidt H, et  al. 
Brain-derived neurotrophic factor V66M polymorphism in childhood-onset 
obsessive–compulsive disorder. Int J Neuropsychopharmacol (2005) 8:133–6. 
doi:10.1017/S146114570400495X 
46. Bloch MH, Landeros-Weisenberger A, Rosario MC, Pittenger C, 
Leckman  JF. Meta-analysis of the symptom structure of obsessive– 
compulsive disorder. Am J Psychiatry (2008) 165:1532–42. doi:10.1176/
appi.ajp.2008.08020320 
47. Walitza S, Marinova Z, Grünblatt E, Lazic SE, Remschmidt H, Vloet TD, et al. 
Trio study and meta-analysis support the association of genetic variation at 
the serotonin transporter with early-onset obsessive-compulsive disorder. 
Neurosci Lett (2014) 580:100–3. doi:10.1016/j.neulet.2014.07.038 
48. Walitza S, Scherag A, Renner TJ, Hinney A, Remschmidt H, Herpertz-
Dahlmann B, et  al. Transmission disequilibrium studies in early onset 
of obsessive–compulsive disorder for polymorphisms in genes of the 
dopaminergic system. J Neural Transm (2008) 115:1071–8. doi:10.1007/
s00702-008-0051-6 
49. Delgrange E, Vasiljevic A, Wierinckx A, Francois P, Jouanneau E, 
Raverot  G, et  al. Expression of estrogen receptor alpha is associated 
with prolactin pituitary tumor prognosis and supports the sex-related 
difference in tumor growth. Eur J Endocrinol (2015) 172(6):791–801. 
doi:10.1530/EJE-14-0990 
50. Lujan R, Shigemoto R, Lopez-Bendito G. Glutamate and GABA receptor 
signalling in the developing brain. Neuroscience (2005) 130(3):567–80. 
doi:10.1016/j.neuroscience.2004.09.042 
51. Dempster EL, Pidsley R, Schalkwyk LC, Owens S, Georgiades A, Kane F, et al. 
Disease-associated epigenetic changes in monocygotic twins discordant for 
schizophrenia and bipolar disorder. Hum Mol Genet (2011) 20(24):4786–96. 
doi:10.1093/hmg/dd416 
52. Uddin M, Sipahi L, Li J, Koenen KC. Sex differences in DNA methylation 
may contribute to risk of PTSD and depression: a review of existing evidence. 
Depress Anxiety (2013) 30(12):1151–60. doi:10.1002/da.22167 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 Nissen, Hansen, Starnawska, Mattheisen, Børglum, Buttenschøn 
and Hollegaard. This is an open-access article distributed under the terms of the 
Creative Commons Attribution License (CC BY). The use, distribution or repro-
duction in other forums is permitted, provided the original author(s) or licensor are 
credited and that the original publication in this journal is cited, in accordance with 
accepted academic practice. No use, distribution or reproduction is permitted which 
does not comply with these terms.
